Brent Blackburn

Brent Blackburn is the CEO and founder of Amygdala Neurosciences. Brent has over 25 years of experience in the pharmaceutical industry, including stints as a senior scientist at Genentech and as the Senior Vice President of Drug Discovery and Development at CV Therapeutics. Blackburn has been instrumental in the development and commercialization of two drugs and the placement of seven products into development for multiple cardiovascular and metabolic indications. In 2009, Gilead Sciences acquired CV Therapeutics.

Brent Blackburn has a PhD in Chemistry from The University of Texas at Austin and a BS in Chemistry and Math from Texas Christian University.

Adrienne MacMillan - CFO & Founder, Mack Mitchell - Chief Medical Officer, and Ivan Diamond - CSO & Founder report to Brent Blackburn.